BR112022026397A2 - Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila - Google Patents

Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila

Info

Publication number
BR112022026397A2
BR112022026397A2 BR112022026397A BR112022026397A BR112022026397A2 BR 112022026397 A2 BR112022026397 A2 BR 112022026397A2 BR 112022026397 A BR112022026397 A BR 112022026397A BR 112022026397 A BR112022026397 A BR 112022026397A BR 112022026397 A2 BR112022026397 A2 BR 112022026397A2
Authority
BR
Brazil
Prior art keywords
methods
heteroaryl
amide derivatives
cancer
treatting
Prior art date
Application number
BR112022026397A
Other languages
English (en)
Portuguese (pt)
Inventor
Li Shijie
Vilalta-Colomer Marta
Zeng Yibin
Zhang Penglie
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112022026397A2 publication Critical patent/BR112022026397A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022026397A 2020-06-23 2021-06-22 Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila BR112022026397A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (1)

Publication Number Publication Date
BR112022026397A2 true BR112022026397A2 (pt) 2023-03-14

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026397A BR112022026397A2 (pt) 2020-06-23 2021-06-22 Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila

Country Status (14)

Country Link
US (3) US20210393759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4167991A4 (cg-RX-API-DMAC7.html)
JP (1) JP7804596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040993A (cg-RX-API-DMAC7.html)
CN (1) CN116472045B (cg-RX-API-DMAC7.html)
AU (1) AU2021297216B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022026397A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187605A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003716A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000703A2 (cg-RX-API-DMAC7.html)
IL (1) IL299206A (cg-RX-API-DMAC7.html)
MX (1) MX2022016554A (cg-RX-API-DMAC7.html)
TW (1) TW202216694A (cg-RX-API-DMAC7.html)
WO (1) WO2021262627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673919B2 (en) * 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US10308644B2 (en) * 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3735410A4 (en) * 2017-10-19 2021-11-03 Tempest Therapeutics, Inc. PICOLINAMIDE COMPOUNDS
WO2019160882A1 (en) * 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165043A2 (en) * 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) * 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases

Also Published As

Publication number Publication date
EP4167991A1 (en) 2023-04-26
US20240115682A1 (en) 2024-04-11
AU2021297216B2 (en) 2025-10-16
CN116472045B (zh) 2025-05-13
EP4167991A4 (en) 2024-07-24
TW202216694A (zh) 2022-05-01
WO2021262627A1 (en) 2021-12-30
CA3187605A1 (en) 2021-12-30
IL299206A (en) 2023-02-01
MX2022016554A (es) 2023-04-10
CL2022003716A1 (es) 2023-06-30
KR20230040993A (ko) 2023-03-23
CO2023000703A2 (es) 2023-01-26
US20250090646A1 (en) 2025-03-20
JP7804596B2 (ja) 2026-01-22
AU2021297216A1 (en) 2023-02-02
JP2023531970A (ja) 2023-07-26
CN116472045A (zh) 2023-07-21
US20210393759A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
BR112022003490A2 (pt) Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
CL2021001508A1 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
BR112023025318A2 (pt) Derivados de triazina e seu uso no tratamento do câncer
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112023019797A2 (pt) Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
PY2126213A (es) Compuestos y métodos para el tratamiento de covid-19
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
BR112021018335A2 (pt) Derivados de benzodiazepina como inibidores de rsv
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
MX2022016554A (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
EA202192433A1 (ru) Соединения, полезные в терапии вич
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112022017779A2 (pt) Imunomodulação de azaletos de o-het-arila
BR112012013854A2 (pt) derivados de oxazina.
BR112021019817A2 (pt) Compostos de pirrol
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
MX2024011130A (es) Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
BR112022005736A2 (pt) Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом